The robotic surgery leader's shares have pulled back, forcing investors to weigh a solid recovery record against new questions in its most important market.

Qualcomm, Intuitive Surgical and Stryker lead today's top analyst reports, spotlighting growth drivers, strategic initiatives and ongoing challenges.

QUALCOMM is expanding beyond smartphones with growth in automotive, edge AI and data centers, but competition and weak China demand remain key challenges.

The market is offering a steep discount on this medical device maker, but the price tag comes with a story about slowing growth. Here’s how to read it.

At $353, Intuitive Surgical (ISRG) is being priced to deliver 14.1% revenue growth annually for the next 4 years simply to defend today's 42.1x multiple. That sits below the 21% the business is currently growing at, which is the unusual part. The multiple has already priced in a slowdown that has not yet appeared.

NZS shifts capital toward AI infrastructure and healthcare leaders

You can be forgiven for doing a double-take on Intuitive Surgical (ISRG) on Friday. The company posted second-quarter revenue of $2.89 billion, up 19% from a year ago and comfortably ahead of Wall Street estimates. Yet the stock ended the day down 14.1%, closing at a new 52-week low.

The surgical robotics giant beat estimates, but a moderation in its core US market has investors questioning the whole story.

Stryker stock has given investors a 28.3% total return over the past five years, yet its current price around US$319.87 sits at a point where the Discounted Cash Flow (DCF) intrinsic value estimate suggests meaningful upside, while market based multiples look closer to fair. Over five years, Stryker has returned 28.3%, which points to steady but not dramatic long term gains for shareholders. New products such as the Mako RPS handheld robotic system can support expectations for future cash...

On 16 July 2026, Stryker announced the U.S. commercial launch of Mako RPS, a handheld robotic system for total knee replacement that combines intraoperative planning with a robotically enabled saw and integrates with its Triathlon Total Knee System and Q Guidance platform. This move extends the Mako ecosystem beyond robotic-arm systems into handheld robotics, potentially broadening adoption by matching robotic precision with familiar surgical workflows. Next, we’ll explore how expanding the...

Stryker (SYK) has drawn fresh attention after announcing the U.S. commercial launch of Mako RPS, a handheld robotic system for total knee replacements that extends its established Mako orthopaedic robotics portfolio. See our latest analysis for Stryker. The U.S. launch of Mako RPS comes as Stryker’s share price sits at US$319.87 after a recent pullback, with a 30 day share price return of 6.22% but a 1 year total shareholder return that declined 17.02%. This suggests enthusiasm around its...

SYK launches Mako RPS, expanding into handheld robotics for total knee replacement and broadening access to robotic-assisted orthopedic procedures.

JNJ beats Q2 estimates and raises 2026 guidance, but shares fall as MedTech misses expectations. Find out what weighed on the unit and what's next.

Abbott’s (ABT) latest financial disclosure reveals a significant strategic evolution that market participants often overlook amidst the focus on quarterly beats. The company is actively executing a structural pivot, shifting its capital allocation and growth dependency away from the volatile Nutrition segment toward high-margin, innovation-led MedTech and specialized diagnostics.

Intuitive Surgical's powerful growth is running headlong into some serious market challenges, and how management framed the collision tells you everything about the real risks.

Johnson & Johnson stock dipped early Wednesday, though the healthcare giant beat second-quarter forecasts and raised its outlook.

Intuitive Surgical stock tumbled Tuesday after HCA Healthcare trimmed its full-year earnings outlook, noting a drop in surgeries.

Here is a way to get paid a meaningful income now on your Intuitive Surgical shares, cash you keep no matter what, in exchange for capping your gains at a price above today's.

This is a product-cycle year for Intuitive Surgical. The company's growth is fueled by hospitals and surgeons adopting its new da Vinci 5 and existing Ion robotic systems.